Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2004

View Archived Issues

Caspase inhibitor reduces platelet function and aggregation in rats

Suppression of testosterone by abiraterone acetate in prostate cancer patients

New evidence on the association between Lp-PLA2 and the risk of CHD and stroke

Clinical benefits of mepolizumab in eosinophilic skin disorders

Characterization of the antiinflammatory effects of topical tacrolimus in atopic dermatitis

NV-1020 enters phase I/II study for liver metastases

Serono concludes licensing agreement

New antibacterial LpxC inhibitors identified at Chiron

Fujisawa presents novel PDE4 and TNF-alpha production inhibitors

FDA response for Lyrica

Novel adenosine A2A antagonists and their use in depression, AD, PD, etc.

CV scientists describe novel fatty acid oxidation inhibitors

Proscar approved for new indication in Canada

New prostanoid EP4 agonists and their use in osteoporosis and other bone disorders

Novel urea-based immunomodulators discovered at Genzyme

Fujisawa claims new HDAC inhibitors for immune disorders, cancer, etc.

Novel DPP-IV inhibitor BMS-477118 shows potential for type 2 diabetes

sBLA filed for Pegasys plus Copegus in HCV patients coinfected with HIV

Fujisawa to submit new data for micafungin in Europe

Phase Ib study completed for ThromboView

Affymax updates pipeline

BIBN-4096BS reveals viability of CGRP receptor antagonism in headache

GW-766994 inhibits early and late phase allergic reactions

MethylGene reviews second quarter progress

Novartis makes good progress on key development projects during H1 2004

New data on the pharmacokinetics of Oralin in type 1 diabetes

An interim analysis provides new evidence of the efficacy of CJC-1131 in type 2 diabetes

Amlodipine/atorvastatin pill effective in diabetics with hypertension and dyslipidemia

Good safety and pharmacokinetic profile of tanaproget in healthy women

Procter & Gamble describes novel orally bioavailable caspase-1 inhibitor

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026